Page 144 - CW E-Magazine (3-6-2025)

Pharmaceuticals

BUSINESS STRATEGY

No plans to enter prescription business in India:

Piramal Pharma

Piramal Pharma has no plans to immediate synergies. “So, the amount to decide and place orders, thus lead-
enter domestic prescription formula- that they can afford to pay versus us… ing to lower capacity utilisation in the
tions business for now, the company’s we wouldn’t have that,” she said. overseas CDMO sites. However, the
chairperson Ms. Nandini Piramal was company’s India sites are running at a
quoted as saying in an Economic Times Piramal Pharma sold its domestic healthy utilisation level, she said. “In
report. formulation business to Abbott for many of our overseas sites, we have
$3.8-bn in 2010. recently made investments and hence
This put to rest speculations that the their utilisation will gradually pick up
company is evaluating acquisitions in On its future growth strategy, the as we fi ll them with new orders,” she
this space. However, the company may chairperson said the company will con- added.
consider acquiring over-the-counter tinue to focus on organic brownfi eld
(OTC) portfolios or individual brands expansion in the drug development About 69% of Piramal Pharma’s
and products for its India-focused and manufacturing service business, revenue comes from regulated markets
consumer healthcare business, which or Contract Development and Manu- like the US, UK, Europe and Japan.
crossed the strategic revenue milestone facturing Organisation (CDMO). The The company is focussing on innova-
of Rs. 1,000-crore in FY25. It may also company is looking at capex of tion and, for the fi rst time, 54% of its
evaluate targets in global complex $100-125 million, she said. CDMO business is innovation related
hospital generics. work. “We have seen strong growth
Talking about the current global in differentiated offerings and we are
Ms. Piramal explained that rivals headwinds, Piramal said near-term seeing good demand in overseas sites.
that already have a prescription busi- macroeconomic uncertainty and uneven However, there is short-term uncertainty
ness would be willing to pay more for improvement in biotech funding is and people are prolonging decision
an acquisition target as they would get leading to customers taking more time making,” Ms. Piramal said.
FUTURE PLANS

Sun Pharma to seek commercialisation partner

for one of its speciality products

Sun Pharmaceutical Industries is to commence Phase II in the second (Rs. 9,576-crore). Gross sales for the year
looking for a partner for the commer- half of 2025. Its ‘MMII’ has completed stood at Rs. 52,041-crore, up 9 percent.
cialisation of its prospective product Phase II trials, the company said. Giving an overview of its business last
MMII, indicated for pain in osteo- Mr. Shanghvi was speaking to analysts year, Mr. Shanghvi said, “Our businesses
arthritis, Mr. Dilip Shanghvi, Sun’s following the announcement of its delivered a robust performance for
Chairman and Managing Director said, Q4-FY25 and annual results for the the year, driven by improving market
as the speciality products segment year ended March 31, 2025 (FY25). share in India and growth in Global
assumes a greater role in the drugmak- Speciality. The near-term pipeline
er’s operations. The company posted a 19 percent in Global Speciality is promising,
dip in net profi t at Rs. 2,149-crore for with products such as ‘Leqselvi’
And as part of a strategic reassess- Q4, as compared to Rs. 2,654-crore and ‘Unloxcyt’ – the latter through our
ment of its global speciality pipeline, in the same year-ago quarter. Its gross recently announced Checkpoint acqui-
Mr. Shanghvi added that they would sales touched Rs. 12,815-crore, a sition – offering signifi cant improve-
look at their Type 2 diabetes-oriented growth of 8.5 percent. The company ments in patient care. We look forward
product ‘GLOO34’, that has completed ended FY25, with a 12 percent net to Speciality becoming an increasingly
its Phase I clinical trial and is looking profi t growth at Rs. 10,929-crore important part of our business.”

144 Chemical Weekly June 3, 2025

Contents Index to Advertisers Index to Products Advertised